Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Reata Pharmaceuticals advances SKYCLARYS, faces impurity challenges and growth opportunities

Reata Pharmaceuticals is making significant progress with FDA approvals and commercialization plans for SKYCLARYS. The company is strategically managing resources and focusing on key programs for long-term sustainability. Challenges with impurity issues and discontinuation of bardoxolone program are being addressed while opportunities for label expansion and new asset exploration are being pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases. It offers antioxidant and inflammation-modulating drugs, as well as drugs that correct protein misfolding. The company also develops drugs for the treatment of renal, cardiovascular, and autoimmune diseases. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005.

Reata Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
The post Stock Upgrades: Reata Pharma Shows Rising Relative Strength appeared first on Investor's Business Daily.

Stock Upgrades: Reata Pharma Shows Rising Relative Strength

FINANCING WILL ADVANCE BARDOXOLONE AS THE FIRST POTENTIAL THERAPY FOR ALPORT SYNDROME, AS WELL AS CONTINUE DEVELOPMENT FOR OTHER RARE AND SERIOUS FORMS OF CHRONIC KIDNEY DISEASE

Reata Pharmaceuticals, Inc. and Blackstone Life Sciences Announce $350 Million Strategic Investment

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago.

Why Is Reata Pharmaceuticals, Inc. (RETA) Down 19.8% Since Last Earnings Report?

Reata (RETA) reports narrower-than-expected loss but misses revenue estimates for first-quarter 2020. Shares down.

Reata (RETA) Q1 Earnings Surpass Estimates, Revenues Miss

Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q1 2020 Results - Earnings Call Transcript

Reata Pharmaceuticals Inc (RETA) delivered earnings and revenue surprises of 54.82% and -53.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Reata Pharmaceuticals Inc (RETA) Reports Q1 Loss, Lags Revenue Estimates

Reata (RETA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Reata (RETA) Stock Might be a Great Pick

ONGOING TRIALS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STOPPED DUE TO HIGH RISK OF COVID-19 TO THESE PATIENTS

Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations

Reata Pharmaceuticals, Inc. (RETA) Down 37.8% Since Last Earnings Report: Can It Rebound?

Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q4 2019 Results - Earnings Call Transcript

Ascendis Pharma

Sarepta Therapeutics

The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2019 portfolio late last week, listing four new holdings.

Vanguard Health Care Fund Adds 4 Stocks to Portfolio in 4th Quarter

Shares of Reata Pharmaceuticals jumped Friday on reports suggesting Amgen could be interested in acquiring the smaller biotech company. Reata is working on a key kidney disease treatment.

How A Rumored Amgen Takeover Sent This Biotech Stock Popping

The capital sets the biotech up nicely to launch two successful drugs.

Reata Pharmaceuticals Just Raised $505 Million to Treat Orphan Diseases: What it Means for Investors

PLANO, Texas, Nov.  18, 2019  (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,760,000 shares of its Class A common stock, which included 360,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $183.00 per share.  The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $505.1 million. 

Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

PLANO, Texas, Nov.  13, 2019  (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,400,000 shares of its Class A common stock at a price to the public of $183.00 per share. The offering was upsized to 2,400,000 shares from the original offering size of 2,000,000 shares. The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $439,200,000.  The offering is expected to close on November 18, 2019, subject to customary closing conditions.  In addition, Reata has granted the underwriters a 30-day option to purchase up to an additional 360,000 shares of Reata’s Class A common stock on the same terms and conditions.

Reata Pharmaceuticals, Inc. Announces Pricing of Upsized Class A Common Stock Public Offering

Reata Pharmaceuticals (RETA) CEO Warren Huff Discusses Positive Topline Pivotal Year 1 CARDINAL Data (Transcript)

Reata Pharmaceuticals: Confusion On The Secondary Endpoint

A drug trial showed promise in treating a particularly stubborn disease.

Why Shares of Reata Pharmaceuticals Rocketed More Than 150% in October

Shares of Reata Pharmaceuticals were briefly halted late Monday just before the biotech company confirmed a recently reacquired kidney disease drug succeeded in a Phase 3 study.

This Biotech Has Rocketed 181% Since October — Did It Just Tap Out?

Reata Pharmaceuticals Inc. shares were halted in the extended session Monday as the biotech drug developer reported positive results from a late-stage kidney disease treatment study.

Reata Pharma kidney drug meets study goals, stock halted

Strong omaveloxolone results in FA was a surprise and could generate $1B+ in sales. Importantly, their Nrf2 activators could potentially treat many other neurodegenerative indications beyond FA.

Reata Is A 'Show Me' Story Showing The Results And With 2 Upcoming Catalysts

Apellis Pharma

Retrophin

Keeping up with the news from major medical meetings has become a requirement for healthcare investors.

3 Companies to Watch At Kidney Week 2019

Reata (RETA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Reata (RETA) Jumps: Stock Rises 5. 6%

The company reclaimed rights to several promising drug candidates last week; this week, positive data from a pivotal clinical trial sent it soaring.

Reata Pharmaceuticals Repositions Itself for Success

Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.

News for Reata Pharmaceuticals Stock (RETA)